Silo pharma issues letter to shareholders detailing progress on pipeline assets combining traditional therapeutics with psychedelic medicine

Englewood cliffs, nj, dec. 01, 2022 (globe newswire) --   silo pharma, inc. ( nasdaq: silo ) (“the company”) , a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today issued a letter to shareholders highlighting the company's progress and potential for its portfolio of novel, ip-protected technologies and assets developed in collaboration with world-class medical research partners. the letter, in its entirety, is reprinted below.
SILO Ratings Summary
SILO Quant Ranking